Patents by Inventor Shawn Iadonato

Shawn Iadonato has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Conotoxin peptide analogs and uses for the treatment of pain and inflammatory conditions
    Patent number: 11612661
    Abstract: Provided herein are alpha-conotoxin peptide analogs, including alpha-conotoxin peptide analogs that are covalently attached to polyethylene glycol (PEG), and pharmaceutical compositions of such alpha-conotoxin peptide analogs. Also provided herein are methods of treating or preventing a condition conducive to treatment or prevention by inhibition of an ?9-containing nicotinic acetylcholine receptor (nAChR) (e.g., the ?9?10 subtype of the nAChR) in a subject.
    Type: Grant
    Filed: January 3, 2020
    Date of Patent: March 28, 2023
    Assignee: Kineta Chronic Pain, LLC
    Inventors: Jose Mercado, Eric J. Tarcha, Jeffrey J. Posakony, Shawn Iadonato
  • CONOTOXIN PEPTIDE ANALOGS AND USES FOR THE TREATMENT OF PAIN AND INFLAMMATORY CONDITIONS
    Publication number: 20200237924
    Abstract: Provided herein are alpha-conotoxin peptide analogs, including alpha-conotoxin peptide analogs that are covalently attached to polyethylene glycol (PEG), and pharmaceutical compositions of such alpha-conotoxin peptide analogs. Also provided herein are methods of treating or preventing a condition conducive to treatment or prevention by inhibition of an ?9-containing nicotinic acetylcholine receptor (nAChR) (e.g., the ?9?10 subtype of the nAChR) in a subject.
    Type: Application
    Filed: January 3, 2020
    Publication date: July 30, 2020
    Applicant: Kineta Chronic Pain, LLC
    Inventors: Jose Mercado, Eric J. Tarcha, Jeffrey J. Posakony, Shawn Iadonato
  • Treatment of obesity and obesity related disorders by pharmalogical targeting of Kv1.3 potassium channels
    Patent number: 9878006
    Abstract: Activation of brown adipose tissue, treatment of obesity and/or treatment of obesity-related disorders in human or non-human animal subjects by administering to the subject a potassium channel inhibiting agent. The potassium channel inhibiting agent may comprise ShK toxin or a modified ShK toxin. Examples of modified ShK toxins include ShK-186.
    Type: Grant
    Filed: February 22, 2016
    Date of Patent: January 30, 2018
    Assignees: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, KINETA ONE, LLC
    Inventors: K. George Chandy, Sanjeev Kumar Upadhayay, Ping H. Wang, Paolo Sassone-Corsi, Kristin Lynn Eckel-Mahan, Shawn Iadonato, Jogesh Mukherjee, M. Reza Mirbolooki
  • Treatment of Obesity and Obesity-Related Disorders by Pharmalogical Targeting of Kv 1.3 Potassium Channels
    Publication number: 20170095530
    Abstract: Activation of brown adipose tissue, treatment of obesity and/or treatment of obesity-related disorders in human or non-human animal subjects by administering to the subject a potassium channel inhibiting agent. The potassium channel inhibiting agent may comprise ShK toxin or a modified ShK toxin. Examples of modified ShK toxins include ShK-186.
    Type: Application
    Filed: February 22, 2016
    Publication date: April 6, 2017
    Inventors: K. George Chandy, Sanjeev Kumar Upadhayay, Ping H. Wang, Paolo Sassone-Corsi, Kristin Lynn Eckel-Mahan, Shawn Iadonato, Jogesh Mukherjee, M. Reza Mirbolooki
  • Treatment of Obesity and Obesity-Related Disorders by Pharmalogical Targeting of Kv 1.3 Potassium Channels
    Publication number: 20150072940
    Abstract: Activation of brown adipose tissue, treatment of obesity and/or treatment of obesity-related disorders in human or non-human animal subjects by administering to the subject a potassium channel inhibiting agent. The potassium channel inhibiting agent may comprise ShK toxin or a modified ShK toxin. Examples of modified ShK toxins include ShK-186.
    Type: Application
    Filed: October 2, 2012
    Publication date: March 12, 2015
    Inventors: K. George Chandy, Sanjeev Kumar Upadhayay, Ping H. Wang, Paolo Sassone-Corsi, Kristin Lynn Eckel-Mahan, Shawn Iadonato, Jogesh Mukherjee, M. Reza Mirbolooki
  • Detection of mutations in a gene associated with resistance to viral infection, OAS1
    Publication number: 20070154467
    Abstract: A method for detecting a mutation related to the gene encoding OAS1. This and other disclosed mutations correlate with resistance of humans to viral infection including hepatitis C. Also provided is a therapeutic agent consisting of a protein or polypeptide encoded by the mutated gene, or a polynucleotide encoding the protein or polypeptide. Inhibitors of human OAS1, including antisense oligonucleotides, methods, and compositions specific for human OAS1, are also provided.
    Type: Application
    Filed: November 2, 2006
    Publication date: July 5, 2007
    Applicant: Illumigen Biosciences, Inc.
    Inventors: Shawn Iadonato, Charles Magness, Gary Rosenberg, Christina Scherer, Thierry Guillaudeux
  • Detection of mutations in a gene associated with resistance to viral infection, OAS2 and OAS3
    Publication number: 20070111231
    Abstract: Compositions and methods are provided for detecting a mutation in a human oligoadenylate synthetase gene, particularly OAS2 or OAS3, wherein the mutation confers resistance to flavivirus infection, including infection by hepatitis C virus, and the mutation relates to other disease states including prostate cancer and diabetes, and uses of the encoded proteins and antibodies thereto.
    Type: Application
    Filed: August 23, 2006
    Publication date: May 17, 2007
    Applicant: Illumigen Biosciences, Inc.
    Inventors: Charles Magness, Shawn Iadonato, Christina Scherer, Phillip Fellin, Kathryn Steiger
  • Mutations in OAS1 genes
    Publication number: 20060275802
    Abstract: Modified amino acid sequences of OAS1 proteins in non-human primates, and genes related thereto, are provided.
    Type: Application
    Filed: May 3, 2006
    Publication date: December 7, 2006
    Inventors: Shawn Iadonato, Charles Magness, P. Fellin, Christina Scherer, Tory Hagen, Amy Olson
  • Detection of mutations in a gene associated with resistance to viral infection, OAS1
    Publication number: 20050191649
    Abstract: A method for detecting a mutation related to the gene encoding OAS1. This and other disclosed mutations correlate with resistance of humans to viral infection including hepatitis C. Also provided is a therapeutic agent consisting of a protein or polypeptide encoded by the mutated gene, or a polynucleotide encoding the protein or polypeptide. Inhibitors of human OAS1, including antisense oligonucleotides, methods, and compositions specific for human OAS1, are also provided.
    Type: Application
    Filed: October 22, 2004
    Publication date: September 1, 2005
    Applicant: Illumigen Biosciences, Inc.
    Inventors: Shawn Iadonato, Charles Magness, Gary Rosenberg, Christina Scherer